Please Note: This trial is no longer enrolling new participants
GO43878 - A PHASE III, OPEN-LABEL, MULTICENTER, RANDOMIZED STUDY EVALUATING GLOFITAMAB AS A SINGLE AGENT VERSUS INVESTIGATOR S CHOICE IN PATIENTS WITH RELAPSED/REFRACTORY MANTLE CELL LYMPHOMA
Protocol No. | CTO-GO43878 | Scope | National |
---|---|---|---|
Principal Investigator | Rita Assi | Treatment Type | Treatment |
Age Group | Adult | Phase | Phase III |